Quick Answer
BeOne Medicines Ltd. reported Total Revenue of $5.34 billion for fiscal year 2025.
BeOne Medicines Ltd. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $5.34B +40.2% |
$3.81B +55.0% |
$2.46B +73.7% |
$1.42B +20.4% |
$1.18B +280.8% |
$308.87M -27.9% |
| Revenue (ASC 606) | $5.34B +40.2% |
$3.81B +55.0% |
$2.46B +73.7% |
$1.42B +20.4% |
$1.18B +280.8% |
$308.87M -27.9% |
| Net Income | $286.93M +144.5% |
-$644.79M +26.9% |
-$881.71M +56.0% |
-$2.00B -37.5% |
-$1.46B +10.3% |
-$1.62B -71.3% |
| Diluted EPS | $0.19 +140.4% |
-$0.47 +27.7% |
-$0.65 +56.4% |
-$1.49 -23.1% |
-$1.21 +19.3% |
-$1.50 -23.0% |
| Total Assets | $8.19B +38.3% |
$5.92B +2.0% |
$5.81B -9.0% |
$6.38B -25.3% |
$8.54B +52.4% |
$5.60B +247.4% |
| Cash and Equivalents | $4.55B +73.1% |
$2.63B -17.2% |
$3.17B -18.0% |
$3.87B -11.6% |
$4.38B +216.6% |
$1.38B +123.6% |
| Long-Term Debt | $961.91M +477.8% |
$166.48M -15.8% |
$197.62M -86.3% |
$1.44B +12.0% |
$1.29B +601.4% |
$183.64M -68.3% |
| Stockholders Equity | $4.36B +30.9% |
$3.33B -5.8% |
$3.54B -19.3% |
$4.38B -28.5% |
$6.13B +58.5% |
$3.87B +302.1% |
| R&D Expense | $2.15B +9.9% |
$1.95B +9.8% |
$1.78B +8.4% |
$1.64B +12.4% |
$1.46B +12.7% |
$1.29B +39.6% |
| Operating Income | $447.14M +178.7% |
-$568.20M +53.0% |
-$1.21B +32.5% |
-$1.79B -24.4% |
-$1.44B +13.2% |
-$1.66B -72.7% |
| Gross Profit | $4.67B +45.3% |
$3.22B +54.7% |
$2.08B +84.1% |
$1.13B +11.7% |
$1.01B | — |
| Shares Outstanding | 1.44B +3.9% |
1.39B +2.0% |
1.36B +0.2% |
1.36B +1.6% |
1.33B +12.1% |
1.19B +48.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $1.41B | +41.0% | +7.4% |
| Revenue (ASC 606) | September 30, 2025 | $1.41B | +41.0% | +7.4% |
| Net Income | September 30, 2025 | $124.84M | +202.9% | +32.4% |
| Diluted EPS | September 30, 2025 | $0.08 | +188.9% | +33.3% |
| Total Assets | September 30, 2025 | $7.63B | +30.9% | +21.2% |
| Cash and Equivalents | September 30, 2025 | $4.04B | +49.4% | +46.5% |
| Long-Term Debt | June 30, 2025 | $146.09M | -89.1% | -8.8% |
| Stockholders Equity | September 30, 2025 | $4.13B | +20.2% | +9.5% |
| R&D Expense | September 30, 2025 | $523.66M | +5.5% | -0.2% |
| Operating Income | September 30, 2025 | $163.11M | +235.6% | +85.6% |
| Gross Profit | September 30, 2025 | $1.22B | +46.3% | +5.7% |
| Shares Outstanding | September 30, 2025 | 1.44B | +3.8% | +0.7% |
- BeOne Medicines Ltd. reported Total Revenue of $5.34 billion for fiscal year 2025.
- BeOne Medicines Ltd. showed an increase of +40.2% in Total Revenue compared to the prior fiscal year.
- BeOne Medicines Ltd. reported Revenue (ASC 606) of $5.34 billion for fiscal year 2025.
- BeOne Medicines Ltd. showed an increase of +40.2% in Revenue (ASC 606) compared to the prior fiscal year.
- BeOne Medicines Ltd. reported Net Income of $286.93 million for fiscal year 2025.
- BeOne Medicines Ltd. showed an increase of +144.5% in Net Income compared to the prior fiscal year.
- BeOne Medicines Ltd. reported Diluted EPS of $0.19 per share for fiscal year 2025.
- BeOne Medicines Ltd. showed an increase of +140.4% in Diluted EPS compared to the prior fiscal year.
- BeOne Medicines Ltd. reported Total Assets of $8.19 billion for fiscal year 2025.
- BeOne Medicines Ltd. showed an increase of +38.3% in Total Assets compared to the prior fiscal year.
- BeOne Medicines Ltd. reported Cash and Equivalents of $4.55 billion for fiscal year 2025.
- BeOne Medicines Ltd. showed an increase of +73.1% in Cash and Equivalents compared to the prior fiscal year.
- BeOne Medicines Ltd. reported Long-Term Debt of $961.91 million for fiscal year 2025.
- BeOne Medicines Ltd. showed an increase of +477.8% in Long-Term Debt compared to the prior fiscal year.
- BeOne Medicines Ltd. reported Stockholders Equity of $4.36 billion for fiscal year 2025.
- BeOne Medicines Ltd. showed an increase of +30.9% in Stockholders Equity compared to the prior fiscal year.
- BeOne Medicines Ltd. reported R&D Expense of $2.15 billion for fiscal year 2025.
- BeOne Medicines Ltd. showed an increase of +9.9% in R&D Expense compared to the prior fiscal year.
- BeOne Medicines Ltd. reported Operating Income of $447.14 million for fiscal year 2025.
- BeOne Medicines Ltd. showed an increase of +178.7% in Operating Income compared to the prior fiscal year.
- BeOne Medicines Ltd. reported Gross Profit of $4.67 billion for fiscal year 2025.
- BeOne Medicines Ltd. showed an increase of +45.3% in Gross Profit compared to the prior fiscal year.
- BeOne Medicines Ltd. reported Shares Outstanding of 1.44 billion shares for fiscal year 2025.
- BeOne Medicines Ltd. showed an increase of +3.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: